Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) Proposers' Day Special Notice

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

Contract Value

Not provided

Codes & Classification
Solicitation Number

ARPA-H-SN-26-139

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

None

Place of Performance

Washington, District of Columbia, UNITED STATES

SourceSAM
Documents3
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a Special Notice (ARPA-H-SN-26-139) to inform the scientific and research community about the upcoming Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program. This notice serves as an official announcement of the associated Proposers’ Day, which is intended to engage potential proposers and provide further details about the program’s objectives and requirements. The ADVOCATE initiative is managed by the Scalable Solutions Office (SSO) within ARPA-H and is designed to foster innovative research and development in the field of cardiovascular care, with a particular emphasis on leveraging agentic artificial intelligence (AI) technologies. The program seeks scalable, transformative solutions that can significantly advance the state of cardiovascular healthcare, potentially improving patient outcomes and care delivery through the integration of advanced AI methodologies. The scope of the procurement is classified under NAICS Code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and is further identified by Product Service Code AN13. The place of performance for this opportunity is Washington, District of Columbia (DC), United States. The contracting entity is ARPA-H, a federal office dedicated to high-impact health research and innovation. Interested parties should note that this is a Special Notice, not a solicitation for proposals at this stage. The notice highlights updates to the SAM.gov reference and FAQs, indicating that further information and clarifications are available in the attached documents. Contractors and research organizations are encouraged to review these materials for comprehensive guidance on program expectations and participation requirements. Key deliverables and objectives for the ADVOCATE program will center on the development and demonstration of agentic AI-enabled solutions for cardiovascular care transformation. While specific technical requirements and milestones are not detailed in this notice, the program’s focus on biotechnology research and scalable innovation suggests that successful proposers will be expected to present robust, evidence-based approaches with clear potential for real-world impact. The notice remains active, with a response deadline set for January 21, 2026. Interested parties should direct inquiries to the provided contact email ([email protected]) and consult the official SAM.gov opportunity listing for additional attachments and updates. In summary, this Special Notice represents a significant opportunity for organizations specializing in biotechnology research and AI-driven healthcare solutions to engage with ARPA-H on a transformative initiative in cardiovascular care. The program’s emphasis on scalability, innovation, and agentic AI positions it as a forward-looking effort to address critical challenges in health outcomes and care delivery.